How Will the HTI-5 Rule Shift IT Risks to Health Systems?

How Will the HTI-5 Rule Shift IT Risks to Health Systems?

Faisal Zain is a seasoned figure in the medical technology landscape, having navigated the intricate intersection of diagnostic innovation and federal oversight for years. As the industry grapples with the recent HHS rollbacks in health IT certification, his perspective offers a crucial bridge between developer efficiency and the frontline realities of clinical safety. In this conversation, we explore the implications of the HTI-5 final rule, which reduces the number of federal certification criteria and shifts the burden of AI transparency and data security directly onto the shoulders of healthcare providers and hospital systems.

With federal health IT certification criteria dropping from 60 to 46, how do you foresee this shift altering the relationship between technology developers and the healthcare systems that implement their tools?

This regulatory slimming down represents a massive pivot in accountability that we haven’t seen in the industry for years. By pruning those 14 criteria and revising seven others, the federal government is essentially handing the steering wheel back to the private sector, which creates a newfound tension in procurement. Developers are breathing a sigh of relief as they look toward the December 28 implementation later this year, but for hospitals, the relief is replaced by a heavy sense of duty. We are moving away from a federal guarantee toward a landscape where health systems must become their own regulators, scrutinizing every line of a contract to ensure the tools they buy are actually safe. It is a transition that feels both liberating for rapid innovation and incredibly daunting for those managing the immediate risks of patient care.

The removal of requirements for source attribution in predictive AI tools seems to create a “black box” scenario for clinicians. What are the practical implications for a doctor trying to trust an AI-driven recommendation at the bedside?

When a predictive tool flags a patient for potential sepsis or suggests a specific intervention, a physician’s first instinct is to ask why, and that is where the removal of source attribute information hurts the most. Without a standardized requirement for transparency regarding training data and performance limitations, we are essentially asking clinicians to operate on blind faith, which is a dangerous precedent. This change strips away the access to modification requirements and intervention risk management that were previously the bedrock of technological trust. Health systems will now have to exert significant pressure during the purchasing phase to demand that developers provide this evidence-based data voluntarily. It adds a layer of friction to the clinical workflow, as leaders must now build their own internal validation and bias-testing frameworks to fill the void left by the ONC.

Beyond AI, the HTI-5 rule also touches on security tags for sensitive health records like behavioral health or substance use disorders. How will the loss of these voluntary certification criteria impact patient privacy and data interoperability?

The elimination of these security tags is perhaps the most unsettling aspect of the new rule because it strikes at the heart of patient trust. While HIPAA remains the law of the land, these tags provided the granular technical ability to shield sensitive records, ensuring that a patient’s history didn’t just flow unchecked into a general summary. Without these standardized tags, providers are left with a massive technical headache, trying to figure out how to respect patient privacy preferences without the right software tools to do so effectively. It makes the task of compliance with sensitive data laws feel like trying to catch water with a sieve. We are losing a common language for data restriction, which could lead to a more fragmented and cautious approach to sharing information between systems.

The government estimates these changes will save over $1.5 billion in regulatory costs, but critics argue this cost is simply being shifted onto hospitals. How do you evaluate the trade-off between developer savings and the increased operational burden on healthcare providers?

That $1.5 billion figure is certainly eye-catching, and from a developer’s standpoint, it represents a significant reduction in the overhead required to bring new technology to market. However, there is no such thing as a free lunch in healthcare regulation; if the cost isn’t being paid during the certification process, it will be paid in the form of intensive legal review and independent validation at the hospital level. Large health systems might have the resources to hire teams for disclosure and validation, but smaller community hospitals may find themselves priced out of the safest technologies. The January 1, 2027, exceptions to these rules are just around the corner, and the scramble to establish internal procurement standards is already causing a palpable sense of anxiety among IT directors. Ultimately, the success of this shift depends on whether the saved billions are reinvested into better product performance or if they simply become a windfall for developers.

What is your forecast for the state of health IT safety over the next few years?

I anticipate a period of significant volatility as we adjust to this decentralized model of oversight starting at the end of this year. We will likely see a surge in the emergence of third-party trust-brokers or private certification bodies that help hospitals vet these 46 remaining criteria and the unregulated gaps left behind. There is a real risk that the quality of AI tools could become highly inconsistent across different regions, depending on how rigorously a local health system can test for bias and accuracy. However, this also opens the door for a more competitive market where developers who choose to be transparent—despite not being required to—will emerge as the preferred partners. In the long run, the industry will have to self-organize to create new safety standards, because the clinical need for reliable, transparent data is too great to ignore, regardless of what the federal minimums require.

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later